An entire nation aligned towards healthcare reform and innovative clinical research with world-class clinics and institutions — where clinical trials can move faster, for less.
Officially Endorsed By Consulate General of Colombia (San Francisco)
Patients here join trials to help move medicine forward and to support their community. Studies fill quickly, and most people stay enrolled through the end.
Faster enrollment, stronger retention.
The whole country runs on U.S. continental time, with direct flights from both coasts. Site monitors can visit midweek and be home by the weekend, and calls happen during normal business hours.
U.S. time zones. Direct flights from both coasts.
A new administration, elected on healthcare reform and in office since August 2026, supports life sciences directly. INVIMA, the national regulator, is opening a faster review pathway for select international sponsors.
Starting with an expedited INVIMA pathway for sponsors.
Cost per patient runs well below the U.S. and Europe. Even next to Australia after its R&D tax rebate, total program costs come out lower — because the savings come from a health system built at scale.
Lower total cost than the U.S., Europe, or Australia.
The case for Colombia, in figures — the national picture first, then a look inside its leading institutions. Every number is tagged by what it measures.
National figures drawn from public sources; institution-level figures verified on-site in Cali & Bogotá. Scope is tagged on each. Full dossiers available under confidentiality.
Colombia's research runs inside accredited academic hospitals and dedicated cancer institutes — with early-phase units, advanced-therapy handling, and certified labs already delivering the full development arc for the world's largest sponsors.
Colombia is home to 54 million people — most of whom have never been offered anything beyond the standard of care.
However, their clinics and institutions have quietly run the world's most demanding trial programs for large pharmaceutical companies for decades.
A new administration — elected on healthcare reform and in office since August 2026 — brings a mandate to transform the healthcare system and incentivize life sciences.
A nation that's aligned — and ready — for the clinical research and infrastructure to support your clinical trials at a speed and efficiency you won't find anywhere else.
Not the ~24 weeks (6 months) that's the global average.
≈ 17 weeks sooner to first patient in.
Colombia's leading institutions have run clinical programs for the most-demanding sponsors — with JCI and CAP accreditations, INVIMA GCP certification, and inspection histories from FDA and EMA without findings.
Merck
Roche
Novartis
Pfizer
AstraZeneca
Sanofi
AbbVie
Bristol Myers Squibb
Eli Lilly
Biogen
Takeda
AbbottList of companies shown above are representative of sponsors that have run or are currently running clinical programs at Colombian clinical institutions. Names and marks belong to their respective owners and are shown for identification, not endorsement.
Reach out to us to find out more about the leading institutions, dedicated principal investigators, and the incredible opportunity across Colombia's clinical landscape.
Let us know about your upcoming programs, priorities or even just some of your wish list items and we will get back to you immediately.
We reply within one business day — and we're glad to put a CDA in place before anything sensitive is exchanged.